Thomson Reuters Corporation: Thomson Reuters Works with Children's Tumor Foundation to Advance Research Efforts
(Thomson Reuters ONE) -
First-of-its-kind disease funding schemas provide a comprehensive view of
neurofibromatosis research
PHILADELPHIA, PA, April 10, 2013 - The Intellectual Property & Science business
of Thomson Reuters, the world's leading provider of intelligent information for
businesses and professionals, today announced a partnership with the Children's
Tumor Foundation (CTF), to further the understanding of neurofibromatosis (NF)
research by creating schemas that visually demonstrate the main pathways
involved in NF and how the organization allocates funds for research and
development.
The Children's Tumor Foundation is a leading nonprofit foundation dedicated to
finding effective treatments for neurofibromatosis, a term for three distinct
genetic disorders: NF1, NF2, and schwannomatosis. NF causes tumors to grow on
nerves throughout the body and affects one in every 3,000 people. There is
currently no known cure and there are relatively few treatment options.
The Children's Tumor Foundation selected Thomson Reuters to construct disease
funding maps for each of the different types of NF. The project was led by the
Thomson Reuters Life Sciences Professional Services team, which started with
MetaCore(TM), an integrated software suite for systems biology that includes the
industry's leading, manually curated, database of biological pathways.
Extracting the key biological processes from the disease pathways and then
merging them with funding data through the MetaCore Pathway Map Creator software
resulted in new pathway maps that give a snapshot of the different biological
processes in each of the NF disease types and the list of grants funded by the
Foundation. Integrated with the maps are dashboards that show how key areas of
the research and development process -such as disease model development,
biomarker population studies and development stage, and drug development status-
are also funded. These interactive visualizations provide a detailed view that
demonstrates how funds are being invested. The disease maps are currently
available on the Children's Tumor Foundation website and the biological content
will be updated annually by Thomson Reuters as part of the ongoing
collaboration.
"Creating a clearer understanding of the various aspects involved in
neurofibromatosis is key to finding effective treatments for NF and connecting
to industry partners who may have drug candidates that are beneficial to our
patients," said Annette Bakker, chief scientific officer of the Children's Tumor
Foundation. "We are pleased to be collaborating with Thomson Reuters on this
project. The visualizations they constructed are helping us achieve our goals by
showcasing which aspects of the disorder have been studied most and which areas
need to be further developed. The disease maps help us guide our funding
strategy and compound scouting efforts."
"We are honored to have been selected by the Children's Tumor Foundation to work
on this important project," said Joe Donahue, senior vice president of Thomson
Reuters Life Sciences business. "The amount of data that is being generated as
new technologies help us better understand the underlying biology of diseases is
enormous. The disease funding schemas will support more informed decision-making
and strategy by researchers and funders by enabling them to more easily identify
which research areas are in greater need of support or activity, and others that
may be making strides toward a cure."
Dr. Annette Bakker will present "Disease Maps and Evaluating New Opportunities:
How the Children's Tumor Foundation and Thomson Reuters are collaborating for a
Better Future," on April 11, 2013 from 9:50 a.m. to 10:20 a.m. at BioIT World in
Boston.
Learn more about MetaCore and Thomson Reuters System Biology Solutions.
Children's Tumor Foundation
The Children's Tumor Foundation is a 501(c)(3) not-for-profit organization
dedicated to finding effective treatments for the millions of people worldwide
living with neurofibromatosis (NF), a term for three distinct disorders: NF1,
NF2, and schwannomatosis. NF causes tumors to grow on nerves throughout the body
and can lead to blindness, bone abnormalities, cancer, deafness, disfigurement,
learning disabilities, and excruciating and disabling pain. NF affects one in
every 3,000 people, more than cystic fibrosis, Duchenne muscular dystrophy, and
Huntington's disease combined. The Children's Tumor Foundation funds critical
research into neurofibromatosis. In addition to benefiting those who live with
NF, this research is shedding new light on several forms of cancer, brain
tumors, bone abnormalities, and learning disabilities, ultimately benefiting the
broader community. For more information, please visit www.ctf.org.
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property, and
science and media markets, powered by the world's most trusted news
organization. With headquarters in New York and major operations in London and
Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates
in over 100 countries. Thomson Reuters shares are listed on the Toronto and New
York Stock Exchanges. For more information, go to www.thomsonreuters.com.
CONTACT
Jen Breen
Thomson Reuters
Jennifer.breen(at)thomsonreuters.com
215-823-1791
Abbey Anderson
Thomson Reuters
abbey.anderson(at)thomsonreuters.com
215-823-1894
Simon Vukelj
Children's Tumor Foundation
svukelj(at)ctf.org
212-344-7568
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1691812]
Unternehmensinformation / Kurzprofil:
Datum: 10.04.2013 - 16:12 Uhr
Sprache: Deutsch
News-ID 247863
Anzahl Zeichen: 6918
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 113 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Corporation: Thomson Reuters Works with Children's Tumor Foundation to Advance Research Efforts"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
